Paper41513625
RECQL4 promotes the malignant progression of lung adenocarcinoma through the YBX1/G3BP1-mediated NF-κB signaling pathway.
Li R and 9 others. Cell Death Discov, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. RECQL4 promotes the malignant progression of lung adenocarcinoma through the YBX1/G3BP1-mediated NF-κB signaling pathway. Papers, record 41513625. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41513625
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- RECQL4 promotes the malignant progression of lung adenocarcinoma through the YBX1/G3BP1-mediated NF-κB signaling pathway.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82472814 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| ts201712087 | Taishan Scholar Foundation of Shandong Province | PubMed |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39216548 | YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. | Cancer Lett | 2024 | https://conductscience.org/library/papers/39216548 | PubMed |
| 2 | 29080750 | Human RecQL4 helicase plays multifaceted roles in the genomic stability of normal and cancer cells. | Cancer Lett | 2018 | https://conductscience.org/library/papers/29080750 | PubMed |
| 3 | 39378549 | Unraveling the mechanisms of RECQL4-mediated cervical cancer progression through the PI3K/AKT pathway. | Transl Oncol | 2024 | https://conductscience.org/library/papers/39378549 | PubMed |
| 4 | 29364287 | The biology and management of non-small cell lung cancer. | Nature | 2018 | https://conductscience.org/library/papers/29364287 | PubMed |
| 5 | 20576703 | The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. | Nucleic Acids Res | 2010 | https://conductscience.org/library/papers/20576703 | PubMed |
| 6 | 31481087 | The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31481087 | PubMed |
| 7 | 28382490 | Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells. | Mol Cell Biochem | 2017 | https://conductscience.org/library/papers/28382490 | PubMed |
| 8 | 29379212 | NF-κB, inflammation, immunity and cancer: coming of age. | Nat Rev Immunol | 2018 | https://conductscience.org/library/papers/29379212 | PubMed |
| 9 | 27601476 | Arginine Demethylation of G3BP1 Promotes Stress Granule Assembly. | J Biol Chem | 2016 | https://conductscience.org/library/papers/27601476 | PubMed |
| 10 | 9632780 | A novel phosphorylation-dependent RNase activity of GAP-SH3 binding protein: a potential link between signal transduction and RNA stability. | Mol Cell Biol | 1998 | https://conductscience.org/library/papers/9632780 | PubMed |
| 11 | 33020468 | G3BP1 controls the senescence-associated secretome and its impact on cancer progression. | Nat Commun | 2020 | https://conductscience.org/library/papers/33020468 | PubMed |
| 12 | 38880223 | YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification. | Cancer Lett | 2024 | https://conductscience.org/library/papers/38880223 | PubMed |
| 13 | 27013200 | Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. | Cancer Res | 2016 | https://conductscience.org/library/papers/27013200 | PubMed |
| 14 | 19657341 | RecQ helicases: multifunctional genome caretakers. | Nat Rev Cancer | 2009 | https://conductscience.org/library/papers/19657341 | PubMed |
| 15 | 38868333 | OmicStudio: A composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication. | Imeta | 2023 | https://conductscience.org/library/papers/38868333 | PubMed |
| 16 | 8031301 | Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. | Bioessays | 1994 | https://conductscience.org/library/papers/8031301 | PubMed |
| 17 | 21045146 | Human RecQL4 helicase plays critical roles in prostate carcinogenesis. | Cancer Res | 2010 | https://conductscience.org/library/papers/21045146 | PubMed |
| 18 | 34946868 | Role and Regulation of the RECQL4 Family during Genomic Integrity Maintenance. | Genes (Basel) | 2021 | https://conductscience.org/library/papers/34946868 | PubMed |
| 19 | 31560169 | Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection. | Cancer Med | 2019 | https://conductscience.org/library/papers/31560169 | PubMed |
| 20 | 36922675 | KIF14 promotes proliferation, lymphatic metastasis and chemoresistance through G3BP1/YBX1 mediated NF-κB pathway in cholangiocarcinoma. | Oncogene | 2023 | https://conductscience.org/library/papers/36922675 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42698848 | YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42698848 | PubMed |
| 42327687 | Differentially Expressed Gene Annotator (DEGAn): automated annotation and analysis of DEGs datasets with OS and PFS data. | Bioinform Adv | 2026 | https://conductscience.org/library/papers/42327687 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| G3BP1 | 10146 | PubTator's text mining | https://conductscience.org/library/genes/10146 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| RECQL4 | 9401 | PubTator's text mining | https://conductscience.org/library/genes/9401 | NCBI Gene |
| YBX1 | 4904 | PubTator's text mining | https://conductscience.org/library/genes/4904 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41513625
GET https://conductscience.org/api/papers/v1/41513625/references?page=2